person · Reporting owner

THOMAS PAUL

Disclosed activity across 7 companies

Tapewire entity: 35286
SEC CIK: 0001166776

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Axogen, Inc.AXGN · Entity 4297	Director	June 24, 2026	June 26, 2026
RTI SURGICAL, INC.RTIX · Entity 159205	Director	March 08, 2019	March 11, 2019
Roka BioScience, Inc.ROKA · Entity 172682	Director · President and CEO	November 10, 2016	November 10, 2016
SURGALIGN HOLDINGS, INC.SRGA · Entity 109633	Director	August 15, 2022	August 17, 2022
TELA Bio, Inc.TELA · Entity 7381	Director	June 09, 2026	June 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Axogen, Inc.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	5,579	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 5,579 · Balance 5,579 F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

RTI SURGICAL, INC.

Report date March 08, 2019 · Filed March 11, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-03-08 transaction · row 1 1 source row Row 1 · 2019-03-08 · Disposition to issuer · Disposed 75,723 · Balance 0 F1: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc." F2: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger. F3: The reporting person will file a Form 4 reflecting his acquisition of the Issuer's securities in connection with the consummation of the Mergers. F4: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020.

Filing footnotes · ownership attribution and instrument terms

F1: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc."

F2: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger.

F3: The reporting person will file a Form 4 reflecting his acquisition of the Issuer's securities in connection with the consummation of the Mergers.

F4: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020.

Roka BioScience, Inc.

Report date November 10, 2016 · Filed November 10, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	85,494	Reported balance After 2016-11-10 transaction · row 1 1 source row Row 1 · 2016-11-10 · Conversion · Acquired 7,143 · Balance 85,494
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-11-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-10 · Conversion · Disposed 50 · Balance 0 F1: Reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converted into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $7.00 per share resulting in his acquisition of 7,143 Common Shares. Common Shares disclosed reflect the October 11, 2016, 10 for 1 reverse stock split of the Company's Common Shares. The Series A Preferred Shares were adjusted proportionately and consequently, each share of Preferred Stock became convertible into approximately 143 shares of common stock. F2: The Series A Preferred Shares automatically converted, upon receipt of Company shareholder approval and had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converted into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $7.00 per share resulting in his acquisition of 7,143 Common Shares. Common Shares disclosed reflect the October 11, 2016, 10 for 1 reverse stock split of the Company's Common Shares. The Series A Preferred Shares were adjusted proportionately and consequently, each share of Preferred Stock became convertible into approximately 143 shares of common stock.

F2: The Series A Preferred Shares automatically converted, upon receipt of Company shareholder approval and had no expiration date.

SURGALIGN HOLDINGS, INC.

Report date August 15, 2022 · Filed August 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,610	Reported balance After 2022-08-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-08-15 · Grant · Acquired 22,857 · Balance 28,610 F1: Represents shares of restricted stock of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. F2: The total shares reported reflect 1:30 reverse stock split on May 17, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of restricted stock of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant.

F2: The total shares reported reflect 1:30 reverse stock split on May 17, 2022.

TELA Bio, Inc.

Report date June 09, 2026 · Filed June 11, 2026

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABIOMED INC

Report date December 22, 2022 · Filed December 27, 2022

Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-12-22 transaction · row 1 1 source row Row 1 · 2022-12-22 · Disposition to issuer · Disposed 6,357 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.

F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.

Aegerion Pharmaceuticals, Inc.

Report date November 29, 2016 · Filed December 01, 2016

Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-11-29 transaction · row 1 1 source row Row 1 · 2016-11-29 · Disposition to issuer · Disposed 36,978 · Balance 0 F1: Disposed of in exchange for 37,924 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2021-08-01	Direct	Reported balance After 2016-11-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-29 · Disposition to issuer · Disposed 23,521 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2022-06-05	Direct	Reported balance After 2016-11-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-29 · Disposition to issuer · Disposed 12,854 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.73 · Expires 2023-06-26	Direct	Reported balance After 2016-11-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-29 · Disposition to issuer · Disposed 14,700 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.55 · Expires 2024-06-26	Direct	Reported balance After 2016-11-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-11-29 · Disposition to issuer · Disposed 5,012 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.98 · Expires 2025-06-26	Direct	Reported balance After 2016-11-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-11-29 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in exchange for 37,924 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."

F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 24, 2026 Filed Jun 26, 2026 20:52 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	5,579	$0.00	$0.00	Disclosure SEC source: 0000805928-26-000088 · wk-form4_1782507169.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,579 Underlying: Common Stock · 5,579 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. Read SEC document
June 19, 2026 Filed Jun 23, 2026 20:36 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionRestricted Stock Units · Derivative	18,867	$0.00	$0.00	Disclosure SEC source: 0000805928-26-000078 · wk-form4_1782246978.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document
June 19, 2026 Filed Jun 23, 2026 20:36 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionCommon Stock	18,867	$0.00	$0.00	Disclosure SEC source: 0000805928-26-000078 · wk-form4_1782246978.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:06 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantStock Option (Right to Buy) · Derivative	17,335	$0.00 Strike: $0.94	$0.00	Disclosure SEC source: 0001166776-26-000002 · form4-06112026_100622.xml · derivative · entry 4 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,335 Underlying: Common Stock · 17,335 shares Expires 2036-06-09 F4 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:06 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantStock Option (Right to Buy) · Derivative	17,550	$0.00 Strike: $0.94	$0.00	Disclosure SEC source: 0001166776-26-000002 · form4-06112026_100622.xml · derivative · entry 3 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2036-06-09 F3 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of June 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:06 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantCommon Stock	11,675	$0.00	$0.00	Disclosure SEC source: 0001166776-26-000002 · form4-06112026_100622.xml · nonDerivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,600 F2 · shares: These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 22:06 UTC	TELA Bio, Inc. TELA · Entity 7381	GrantCommon Stock	11,925	$0.00	$0.00	Disclosure SEC source: 0001166776-26-000002 · form4-06112026_100622.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,925 F1 · shares: These restricted stock units will vest in three equal annual installments beginning on June 9, 2027, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
December 09, 2025 Filed Dec 10, 2025 22:19 UTC	Axogen, Inc. AXGN · Entity 4297	SaleCommon Stock	21,399	$29.61	$633,709.99	Disclosure SEC source: 0000805928-25-000161 · wk-form4_1765405158.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,528 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.56 to $29.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 19, 2025 Filed Jun 20, 2025 20:07 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	18,867	$0.00	$0.00	Disclosure SEC source: 0000805928-25-000096 · wk-form4_1750450032.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,867 Underlying: Common Stock · 18,867 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document
September 16, 2024 Filed Sep 17, 2024 20:14 UTC	Axogen, Inc. AXGN · Entity 4297	GrantCommon Stock	2,875	Not disclosed	Not disclosed	Disclosure SEC source: 0000805928-24-000131 · wk-form4_1726604047.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,927 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock in connection with his appointment as Chairman of the Board of Directors. Read SEC document
September 01, 2024 Filed Sep 5, 2024 00:33 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionRestricted Stock Units · Derivative	11,904	$0.00	$0.00	Disclosure SEC source: 0000805928-24-000117 · wk-form4_1725494029.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. Read SEC document
September 01, 2024 Filed Sep 5, 2024 00:33 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionCommon Stock	11,904	$0.00	$0.00	Disclosure SEC source: 0000805928-24-000117 · wk-form4_1725494029.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024. Read SEC document
June 06, 2024 Filed Jun 10, 2024 22:19 UTC	Axogen, Inc. AXGN · Entity 4297	GrantEmployee Stock Option (right to purchase) · Derivative	18,248	$0.00 Strike: $7.04	$0.00	Disclosure SEC source: 0000805928-24-000097 · wk-form4_1718057952.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,248 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document
June 06, 2024 Filed Jun 10, 2024 22:19 UTC	Axogen, Inc. AXGN · Entity 4297	GrantCommon Stock	10,653	Not disclosed	Not disclosed	Disclosure SEC source: 0000805928-24-000097 · wk-form4_1718057952.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,148 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Read SEC document
September 01, 2023 Filed Sep 7, 2023 10:30 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	11,904	$0.00	$0.00	Disclosure SEC source: 0000805928-23-000116 · wf-form4_169408264223286.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document
September 01, 2023 Filed Sep 7, 2023 10:30 UTC	Axogen, Inc. AXGN · Entity 4297	GrantEmployee Stock Option (right to purchase) · Derivative	20,436	$0.00 Strike: $6.30	$0.00	Disclosure SEC source: 0000805928-23-000116 · wf-form4_169408264223286.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document
June 01, 2023 Filed Jun 5, 2023 22:22 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionRestricted Stock Units · Derivative	6,459	$0.00	$0.00	Disclosure SEC source: 0000805928-23-000058 · wf-form4_168600374905379.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 22:22 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionCommon Stock	6,459	$0.00	$0.00	Disclosure SEC source: 0000805928-23-000058 · wf-form4_168600374905379.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:21 UTC	ABIOMED INC NASD · Entity 121309	Disposition to issuerCommon Stock, $.01 par value	6,357	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-22-013000 · form4-12272022_101244.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · kind: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F1 · price: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · price: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. Read SEC document
November 01, 2022 Filed Nov 3, 2022 16:50 UTC	ABIOMED INC NASD · Entity 121309	SaleCommon Stock, $.01 par value	1,000	$379.38	$379,380.00	Disclosure SEC source: 0001415889-22-011063 · form4-11032022_011156.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,357 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $379.3800. Detailed information regarding the number of shares sold at each separate price willbe provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 15, 2022 Filed Aug 17, 2022 16:47 UTC	SURGALIGN HOLDINGS, INC. SRGA · Entity 109633	GrantCommon Stock	22,857	$0.00	$0.00	Disclosure SEC source: 0001209191-22-046168 · doc4.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,610 F1 · shares: Represents shares of restricted stock of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. F2 · balance_after: The total shares reported reflect 1:30 reverse stock split on May 17, 2022. Read SEC document
August 11, 2022 Filed Aug 12, 2022 16:10 UTC	ABIOMED INC NASD · Entity 121309	Tax withholdingCommon Stock, $.01 par value	232	$293.34	$68,054.88	Disclosure SEC source: 0001415889-22-008531 · form4-08122022_010818.xml · nonDerivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 F2 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F2 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
August 10, 2022 Filed Aug 12, 2022 16:10 UTC	ABIOMED INC NASD · Entity 121309	GrantCommon Stock, $.01 par value	681	$0.00	$0.00	Disclosure SEC source: 0001415889-22-008531 · form4-08122022_010818.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,589 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a Time-Based Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a Time-Based Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:16 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	6,459	$0.00	$0.00	Disclosure SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · derivative · entry 4 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Common Stock · 6,459 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:16 UTC	Axogen, Inc. AXGN · Entity 4297	GrantStock Option (right to purchase) · Derivative	11,811	$0.00 Strike: $9.29	$0.00	Disclosure SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · derivative · entry 3 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 Underlying: Common Stock · 11,811 shares Expires 2032-06-01 F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:16 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionRestricted Stock Units · Derivative	3,036	$0.00	$0.00	Disclosure SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:16 UTC	Axogen, Inc. AXGN · Entity 4297	GrantCommon Stock	3,036	$0.00	$0.00	Disclosure SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022. Read SEC document
August 18, 2021 Filed Aug 19, 2021 16:17 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock, $.01 par value	663	$330.77	$219,300.51	Disclosure SEC source: 0001179110-21-008306 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,908 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F1 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $330.7687. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 12, 2021 Filed Aug 13, 2021 16:30 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $.01 par value	245	$319.88	$78,370.60	Disclosure SEC source: 0001179110-21-008178 · edgar.xml · nonDerivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,571 F2 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F2 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
August 11, 2021 Filed Aug 13, 2021 16:30 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock, $.01 par value	625	$0.00	$0.00	Disclosure SEC source: 0001179110-21-008178 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,816 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 11, 2022; or (b) the date of the Issuer's next annual meeting of stockholders. F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 11, 2022; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
June 01, 2021 Filed Jun 3, 2021 21:14 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	3,036	$0.00	$0.00	Disclosure SEC source: 0000805928-21-000112 · wf-form4_162275486446760.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 Underlying: Common Stock · 3,036 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document
June 01, 2021 Filed Jun 3, 2021 21:14 UTC	Axogen, Inc. AXGN · Entity 4297	GrantStock Option (right to buy) · Derivative	6,030	$0.00 Strike: $19.76	$0.00	Disclosure SEC source: 0000805928-21-000112 · wf-form4_162275486446760.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires 2031-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document
May 07, 2021 Filed May 10, 2021 21:28 UTC	SURGALIGN HOLDINGS, INC. SRGA · Entity 109633	GrantCommon Stock	57,803	$0.00	$0.00	Disclosure SEC source: 0001209191-21-031336 · doc4.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,218 F1 · shares: Represents restricted stock units of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document
May 07, 2021 Filed Jul 2, 2021 20:52 UTC Amendment	SURGALIGN HOLDINGS, INC. SRGA · Entity 109633	GrantCommon Stock	72,254	$0.00	$0.00	Disclosure SEC source: 0001209191-21-045030 · doc4a.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,669 F1 · shares: The Form 4 filed on 5/10/2021 representing restricted stock units of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant erroneously reported 57,803 RSUs in column four. The purpose of this amendment is to correct the total underlying shares in columns four and five. Read SEC document
September 30, 2020 Filed Oct 2, 2020 20:10 UTC	Axogen, Inc. AXGN · Entity 4297	GrantStock Option (right to purchase) · Derivative	45,910	$0.00 Strike: $11.63	$0.00	Disclosure SEC source: 0001179110-20-010142 · edgar.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,910 Underlying: Common Stock · 45,910 shares Expires 2030-09-30 F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest annually in equal parts over a three year period and become fully vested on September 30, 2023 Read SEC document
August 12, 2020 Filed Aug 14, 2020 16:12 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock, $.01 par value	661	$0.00	$0.00	Disclosure SEC source: 0001179110-20-009050 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,191 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 12, 2021; or (b) the date of the Issuer's next annual meeting of stockholders. F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 12, 2021; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
August 10, 2020 Filed Aug 11, 2020 16:07 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock, $.01 par value	2,000	$303.41	$606,820.00	Disclosure SEC source: 0001179110-20-008872 · edgar.xml · nonDerivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,530 F2 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · price: This price represents the sale price of the transactions on the reported date at $303.413. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 07, 2020 Filed Aug 11, 2020 16:07 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $.01 par value	390	$314.98	$122,842.20	Disclosure SEC source: 0001179110-20-008872 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,530 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:23 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock, $.01 par value	2,000	$151.78	$303,561.20	Disclosure SEC source: 0001179110-20-003080 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,920 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F1 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the weighted average sale price of multiple transactions on the reported date at a price of $151.7806. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
February 26, 2020 Filed Mar 2, 2020 18:42 UTC	SURGALIGN HOLDINGS, INC. RTIX · Entity 109633	GrantCommon Stock	24,692	$0.00	$0.00	Disclosure SEC source: 0001209191-20-014372 · doc4.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,415 F1 · shares: Represents shares of restricted stock of RTI Surgical Holdings, Inc. (the "Company") granted to Mr. Thomas as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document
February 10, 2020 Filed Feb 12, 2020 17:14 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock, $.01 par value	2,000	$181.13	$362,250.40	Disclosure SEC source: 0001179110-20-001520 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,920 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F1 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the weighted average sale price of multiple transactions on the reported date at a price of $181.1252. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 08, 2019 Filed Aug 9, 2019 16:38 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $.01 par value	245	$189.93	$46,532.85	Disclosure SEC source: 0001179110-19-009349 · edgar.xml · nonDerivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,920 F2 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F2 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
August 07, 2019 Filed Aug 9, 2019 16:38 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock, $.01 par value	1,053	$0.00	$0.00	Disclosure SEC source: 0001179110-19-009349 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,165 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 7, 2020; or (b) the date of the Issuer's next annual meeting of stockholders. F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 7, 2020; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
March 08, 2019 Filed Mar 11, 2019 13:26 UTC	RTI SURGICAL, INC. RTIX · Entity 159205	Disposition to issuerCommon Stock	75,723	Not disclosed	Not disclosed	Disclosure SEC source: 0001100441-19-000009 · primary_doc.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc." F2 · price: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger. F3 · price: The reporting person will file a Form 4 reflecting his acquisition of the Issuer's securities in connection with the consummation of the Mergers. F4 · price: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020. Read SEC document
March 08, 2019 Filed Mar 11, 2019 17:32 UTC	SURGALIGN HOLDINGS, INC. RTIX · Entity 109633	GrantCommon Stock	75,723	Not disclosed	Not disclosed	Disclosure SEC source: 0001760173-19-000023 · primary_doc.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,723 F1 · price: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc." F2 · price: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger. F3 · price: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020. Read SEC document
February 26, 2019 Filed Feb 27, 2019 14:55 UTC	RTI SURGICAL, INC. RTIX · Entity 159205	GrantCommon Stock	21,322	$0.00	$0.00	Disclosure SEC source: 0001100441-19-000002 · primary_doc.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,723 F1 · shares: Represents shares of restricted stock of RTI Surgical, Inc.(the "Company") granted to Mr. Thomas as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document
August 08, 2018 Filed Aug 10, 2018 20:11 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $.01 par value	591	$376.01	$222,221.91	Disclosure SEC source: 0001179110-18-010522 · edgar.xml · nonDerivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,112 F2 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F2 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
August 08, 2018 Filed Aug 10, 2018 20:11 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock, $.01 par value	531	$0.00	$0.00	Disclosure SEC source: 0001179110-18-010522 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,703 F1 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 8, 2019; or (b) the date of the Issuer's next annual meeting of stockholders. F1 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) August 8, 2019; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document
February 28, 2018 Filed Mar 1, 2018 13:11 UTC	RTI SURGICAL, INC. RTIX · Entity 159205	GrantCommon Stock	17,647	$0.00	$0.00	Disclosure SEC source: 0001100441-18-000003 · primary_doc.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,401 F1 · shares: Represents shares of restricted stock of RTI Surgical, Inc. (the "Company") granted to Mr. Thomas as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document
August 15, 2017 Filed Aug 17, 2017 16:22 UTC	ABIOMED INC ABMD · Entity 121309	SaleCommon Stock, $.01 par value	10,000	$154.71	$1,547,075.00	Disclosure SEC source: 0001179110-17-011618 · edgar.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,172 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F1 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.